HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Beauchesne, P. Articles by Soler, C. Search for Related Content PubMed PubMed Citation Articles by Beauchesne, P. Articles by Soler, C.

^99mTc-Sestamibi Brain SPECT After Chemoradiotherapy Is Prognostic of Survival in Patients with High-Grade Glioma

¹ Institut National de la Santé et de la Recherche Médicale, Unité 453, Centre Léon Bérard, Lyon, France
² Service de Neurochirurgie, Centre Hospitalier Universitaire, Saint-Etienne, France
³ Centre d’Imagerie Nucléaire, Saint-Etienne, France

This prospective clinical study used ^99mTc-sestamibi (MIBI) brain SPECT to assess residual tumor volume and determine whether it would be prognostic of survival at the end of cranial irradiation in patients with malignant glioma. Methods: Fifty-seven patients with supratentorial malignant glioma were included in this clinical trial. Tomoscintigraphy was performed 4 h after an intravenous injection of MIBI (1,110 MBq). The images were obtained from a dual-head -camera using fanbeam collimators. Transverse, coronal, and sagittal views were reconstructed. Metabolic tumor volume (MTV), using an ellipsoid model, was calculated from the 3 slices. The first posttherapeutic neuroradiologic evaluation was performed at the end of each patient’s radiation therapy. Results: ^99mTc-MIBI brain SPECT performed at the end of cranial irradiation provided data that allowed the identification of residual tumor and could be used to accurately predict survival of malignant glioma patients, taking into account the established prognostic factors. Patients with an MTV < 32 cm³ had a median survival of 358 d, as opposed to 238 d in patients with an MTV 32 cm³ (P = 0.05). Moreover, half of CT scans performed at the same time were considered to show doubtful or only suggestive findings. No diagnosis of tumor progression or inflammatory changes was possible. Conclusion: ^99mTc-MIBI brain SPECT may help in establishing the prognosis of glioma patients at the end of radiation therapy. Consequently, the management of patients can be adapted. These new data should be considered in the design of future clinical studies of malignant glioma patients as a way to quickly assess the efficiency of therapies.

Key Words: malignant glioma • radiation therapy • ^99mTc-sestamibi brain SPECT • survival time

This article has been cited by other articles:

				P. Beauchesne LETTER TO THE EDITOR: In Reference to Alexiou et al. (Neuro-Oncology 2008;10:104-105) Neuro Oncology, August 1, 2008; 10(4): 643 - 643. [Full Text] [PDF]